Cross-Sector entity
EVERTEC is the most frequent co-covered peer, appearing in 3 of the 4 tracked stories. pharma accounts for 2 of the 4 tracked stories, while 2 other categories carry the remainder. We currently track 4 Cross-Sector stories that mention Lantheus, published between February 25, 2026 and February 26, 2026.
4 verified stories tracked
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
EVERTEC is the most frequent co-covered peer, appearing in 3 of the 4 tracked stories. pharma accounts for 2 of the 4 tracked stories, while 2 other categories carry the remainder. We currently track 4 Cross-Sector stories that mention Lantheus, published between February 25, 2026 and February 26, 2026. Each carries 6 original sources on average.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Lantheus. Shared-story counts are live from our verified record — not editorial picks.
The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.
A diverse group of mid-cap leaders across home services, healthcare, and fintech are preparing to release their quarterly results. Investors are focused on subscriber retention at Frontdoor and the continued clinical adoption of diagnostics at Natera and Lantheus.
As the Q4 2025 earnings cycle concludes, investors are prioritizing results from Natera and Lantheus to gauge the health of the liquid biopsy and radiopharmaceutical markets. These reports will provide critical data on the adoption of minimal residual disease (MRD) testing and the competitive dynamics of prostate cancer imaging.
Investors are closely monitoring upcoming earnings from Natera and Lantheus as bellwethers for the precision medicine and radiopharmaceutical sectors. These reports will highlight the scaling of molecular residual disease testing and the competitive dynamics of advanced prostate cancer imaging.
Source: markets.financialcontent.com · markets.financialcontent.com
